ArticleAnnals of the rheumatic diseases2017
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.
Article in Annals of the rheumatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review.International ophthalmology · 2022Pooled it
- Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study.Blood cancer journal · 2025Article
- CD5Discover oncology · 2025Article
- Immunosuppressants/Immunomodulators and Malignancy.Journal of clinical medicine · 2025Review
- Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in US Veterans with rheumatoid arthritis.BMC rheumatology · 2025Article
- The association between inefficient repair of oxidative DNA lesions and common polymorphisms of the key base excision repair genes as well as their expression levels in patients with rheumatoid arthritis.Archives of medical science : AMS · 2025Article
- Autoimmune disease-associated lymphomas: research progress and review.Frontiers in immunology · 2025Review
- [Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- Large-scale real-world data analyses of cancer risks among patients with rheumatoid arthritis.International journal of cancer · 2023Article
- [DMARD (disease-modifying antirheumatic drug) treatment in patients with former or current cancer].Zeitschrift fur Rheumatologie · 2023Review
- [Celebrating 33 years of the DRFZ: Epidemiology and Health Services Research].Zeitschrift fur Rheumatologie · 2022Review
- Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab: illustrative case.Journal of neurosurgery. Case lessons · 2022Article
- Article
- Article
- [Treatment of rheumatoid arthritis and spondylarthritis with biologics].Der Internist · 2022Review
- Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy.Frontiers in immunology · 2022Article
- Understanding the enigmatic association between mycosis fungoides and psoriasis: Report of two cases and review of the literature.Metabolism open · 2021Review
- KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities.Journal of rheumatic diseases · 2021Review
- Lymphoma complicating rheumatoid arthritis: results from a French case-control study.RMD open · 2021Article
- Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).Experimental and therapeutic medicine · 2021Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 16 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes.
methodsPatients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD.
resultsAmong 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population.
conclusionThis large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.